

## Drug Misuse Prevention Committee meeting

**Date:** 03/03/2016

**Location:** Avonmouth House, 6 Avonmouth Street, London, SE1 6NX

**Minutes:** Final

<b>Committee members present:</b>	
David Croisdale-Appleby (Chair)	(Present for notes 1 – 10)
Rachel Bundock (Topic Expert)	(Present for notes 1 – 10)
Ross Cowan (Community Core)	(Present for notes 1 – 10)
Hiten Dodhia (Core)	(Present for notes 1 – 10)
Rose Durban (Core)	(Present for notes 1 – 10)
Eileen Kaner (Core)	(Present for notes 1 – 10)
Jasmine Murphy (Core)	(Present for notes 1 – 10)
Blaine Stothard (Topic Expert)	(Present for notes 1 – 10)
April Wareham (Community Topic Expert)	(Present for notes 1 – 10)

<b>In attendance:</b>		
Adrienne Cullum	Technical Lead, NICE	(Present for items 1 – 10)
Ella Novakovic	Senior Technical Analyst, NICE	(Present for items 1 – 10)
Aedin McSloy	Assistant Technical Analyst, NICE	(Present for items 1 – 10)
Lesley Owen	Health Economist, NICE	(Present for items 4 – 13)
Simon Moore	Expert testimony: Professor of Public Health Research, Cardiff University	(Present for item 4)
Brendan Collins	Liverpool University	(Present for items 5 – 13)
Anthony Martin	Liverpool University	(Present for items 5 – 13)

## PHAC C minutes 3<sup>rd</sup> March 2016

### Observers:

Rosie Benneyworth	(Present for items 1 – 5)
Simon Ellis	(Present for items 1 – 4)

### Apologies:

Paul McArdle	Topic Expert
Janis Baird	Core
Stephen Morris	Core
Kamran Siddiqi	Core
Harry Sumnall	Co-opted member
Ian Wall	NICE

### 1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the fourth meeting on Drug Misuse Prevention. The Committee members and attendees introduced themselves.

The Chair welcomed the observers to the meeting. There were no members of the public in attendance.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair informed the Committee of the resignation of Jim McCambridge due to his concerns about evidence review 1, that the Committee had previously discussed. NICE will commission an external review of evidence review 1 to ensure it is fit for purpose. This will not prevent the Committee from discussing the evidence and drafting the recommendations. The Chair informed the Committee of the appointment of Harry Sumnall as a co-opted member to ensure that the Committee have access to academic expertise in this topic area. It was noted that the Committee should regard Harry Sumnall as a contractor during discussions of the economic modelling due to his involvement in the economic evidence review.

The Chair reminded all present that the Committee is independent and advisory, that its decisions and recommendations to NICE do not represent final NICE guidance, and that they may be changed as a result of public consultation.

The Chair outlined the objectives of the meeting, which included:

- Hearing expert testimony

## PHAC C minutes 3<sup>rd</sup> March 2016

- Discussing the economic modelling
- Discussing evidence review 2 group 10
- Drafting recommendations, committee discussion and research recommendation

### **2. Confirmation of matter under discussion, and declarations of interest**

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was in relation to 'Drug misuse prevention: targeted interventions'.

The Chair asked everyone to verbally declare any interests that have arisen since the last meeting.

Name	Job title, organisation	Declarations of Interest, date declared	Decision taken
Janis Baird	Associate Professor of Public Health Medicine, MRC Lifecourse Epidemiology Unit	I and a group of colleagues at the MRC Lifecourse Epidemiology Unit, University of Southampton, have received funding from Danone Nutrica Early Life Nutrition for a specific research study which aims to improve the nutrition and Vitamin D status of pregnant women.	
		I am a member of the NIHR Research for Patient Benefit South Central Advisory Committee	
Rachel Bundock	Young People's Director, Compass	Executive Director - Compass (Voluntary sector organisation) that competitively bids to provide a range of drug prevention, early intervention, targeted and specialist substance misuse and risk taking behaviour services for children and young people across a number of local authorities.	
Ross Cowan	Community core member	Unpaid Trustee of the Health and Race Equality Forum (HAREF), a small charity based in Newcastle which receives funding to carry out involvement and engagement activities around health and related issues.	
		Health and Wellbeing Policy Associate with Voluntary Organisations Network North East	

## PHAC C minutes 3<sup>rd</sup> March 2016

		which receives funding from, and is a part of, Regional Voices, one of 21 voluntary sector networks and organisations in the DH, NHS England and Public Health England Strategic Partners Programme.	
David Croisdale-Appleby	Professor/Executive Chair, Standing Commission on Carers	<p>Chair of Skills for Care 2008 – 2014</p> <p>Chair of Skills for Care and Development 2008 – 2014</p> <p>Chair of Hft 2010 – 2015</p> <p>Executive Chair of the Standing Commission on Carers 2014 – present</p> <p>Chair of Dementia UK 2013 – present</p> <p>Board Member of Health Education England 2014 - present</p> <p>Board Member of Think Ahead 2014 – present</p> <p>Member, Cross-Government Council on the New Carers Strategy 2015 – present</p> <p>Professor at the School of Medicine and Health, Durham University</p> <p>Professor at the Wolfson Research Institute for Health and Wellbeing</p> <p>Professor at the Durham University Business School</p> <p>Visitor/Inspector of Medical Education, General Medical Council 2001 – present</p>	
Hiten Dodhia	Assistant Director Health Intelligence & Analysis/Consultant in Public Health, Southwark Council	None	

## PHAC C minutes 3<sup>rd</sup> March 2016

Rose Durban	Director, RGC Consulting Ltd	Through my company, RGC Consulting Ltd, I undertake some part-time work as an adviser for the DfE (Department for Education) providing children's social care advice, support and challenge to those local authorities in intervention following adverse Ofsted inspection judgement on their Children's Services arrangements.	
Eileen Kaner	Professor of Public Health Research, Newcastle University	I am a Professor of Public Health and Primary Care Research at Newcastle University and have formed conclusions, derived from evidence, on primarily alcohol and public health issues. I have also previously chaired a NICE PDG (PH24) focused on alcohol and prevention. The work of my current PHAC has not covered these areas of my expertise. Hence I believe I have no non-pecuniary personal or professional conflicts to declare.	
		I am a member of the NIHR Public Health funding board.	
		I also have a number of funded studies that focus on alcohol and substance use in several of the groups focussed on including looked after children, people in criminal justice systems, people with mental health & substance use problems.	
		I also have an alcohol research UK PhD studentship on family involved interventions for young people with substance use and mental health problems	
Paul McArdle	Consultant Child and Adolescent Psychiatrist, Northumberland Tyne and Wear NHS Foundation Trust	None	
Jim McCambri	Prof, Addictive Behaviours & Public Health,	I have recently been awarded a research grant by NIHR-PHR to do a systematic review of novel	

## PHAC C minutes 3<sup>rd</sup> March 2016

dge	University of York	psychoactive substances  I have co-authored papers that may be considered as part of the evidence review for this guideline.	
Stephen Morris	Professor of Health Economics, University College London	From October 2014 to June 2015 I received consultancy fees from Health Education North Central and East London to undertake a scoping project to evaluate the future need for Speech and Language Therapists in London.	
		From January 2015 to July 2015 I received consultancy fees from social enterprise Oomph Wellness to undertake a pilot study to evaluate the cost-effectiveness of the Oomph! programme, which provides exercise and activity classes for older people in care homes.	
		From September 2011 to September 2012 I received consultancy fees from GlaxoSmithKline to undertake a cost-effectiveness analysis of mepolizumab in adults and adolescents with severe asthma.	
		From September 2011 to the present I have been a member of the NIHR Public Health Research Programme Research Funding Board.	
		From October 2014 to the present I have been a member of the NIHR Health Services and Delivery Research Programme Funding Board.	
		From April 2015 to the present I have been a member of the NIHR Programme Grants for Applied Research expert sub-panel.	
Jasmine Murphy	Consultant in Public Health, Leicester City Council	None	
Kamran Siddiqi	Clinical Senior Lecturer, University of	On behalf of my institution (University of York), I have received research funding from MRC, NIHR, CRUK (a cancer charity involved in advocacy	

## PHAC C minutes 3<sup>rd</sup> March 2016

	York	<p>for cancer patients), and IDRC (International Development Research Centre in Canada).</p>	
		<p>I work at the Institute of Health Sciences at University of York that has an interest in a number of public health areas of research and have secured research grants from NIHR, MRC and several other organizations for a variety of public health topics</p>	
		<p>I have a personal academic interest in a number of public health research topics including tobacco cessation, second-hand smoking, preventing tobacco uptake and ethnicity and health. I have written and presented on these topics</p>	
Blaine Stothard	Prevention Specialist, Blaine Stothard Consultancy	<p>I have written journal articles and authored and co-authored book chapters on drug policy and drug prevention.</p> <p>I have contributed to teaching resources on drug education.</p> <p>I am co-editor of the journal Drugs and Alcohol Today.</p>	
Harry Sumnall	Professor in Substance Use	<p>Member – Advisory Committee on Misuse of Drugs (ACMD)</p> <p>Board member – Mentor UK</p> <p>Board member – EU Society for Prevention Research</p> <p>Co-I NIHR grant on prevention related topic</p> <p>Member of a University Department with broad research interests in the topic</p>	
April Wareham	Community topic expert member	<p>As an independent consultant trainer I have been paid by Martindale Pharma to deliver training to drug and alcohol professionals/prisons staff/policy/social workers etc. in the use of Prenoxad (naloxone hydrochloride 1mg/1ml). September 2014 to date</p> <p>Director of Working with Everyone: we were contracted on a consultancy basis by Martindale Pharma to deliver a number of training sessions to</p>	

## PHAC C minutes 3<sup>rd</sup> March 2016

		<p>Boots pre-reg pharmacists. February 2015</p> <p>Director SMMGP: the organisation receives sponsorship for its Annual Conference from a number of organisations, including pharmaceutical companies. The organisation has received education grants from various pharmaceutical companies. Ongoing</p>	
<p>The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.</p>			
<p><b>3. Minutes of last meeting</b></p>			
<p>The Chair asked the Committee if it wanted any changes made to the minutes of the last meeting. The Committee agreed that the minutes were a true and accurate account of the meeting.</p>			
<p>The Chair informed the Committee that the Home Office had declined to provide expert testimony with the reason that he did not feel able to provide any addition information from that of PHE. The Committee were content with this response.</p>			
<p><b>4. Expert Testimony session: night time economy and multi-agency working</b></p>			
<p>The Chair introduced Professor Simon Moore, Professor of Public Health Research, Cardiff University, who gave a presentation on the night-time economy and multi-agency working.</p>			
<p>The Committee were given the opportunity to ask questions.</p>			
<p><b>Action: Simon Moore to provide NICE with his slides</b></p>			
<p><b>Action: Members to forward any additional questions from committee for Simon Moore.</b></p>			
<p><b>Action: NICE to circulate received expert testimony paper in advance of the next meeting.</b></p>			
<p>The Chair thanked Simon for his presentation.</p>			
<p><b>5. Implications for expert testimony for recommendations</b></p>			
<p>The Committee discussed considerations that resulted from the expert testimony.</p>			

**6. Economic modelling- initial findings**

The Chair introduced Brendan Collins, Research Fellow in Health Economics at the University of Liverpool and Anthony Martin, Research Fellow in Health Economics at the University of Liverpool, who gave a presentation on the initial findings from the economic modelling.

The Committee discussed questions emailed from Stephen Morris and were also given the opportunity to ask questions. Lesley Owen, Health economist, NICE, was also present to answer questions.

The Chair thanked Brendan and Anthony for their presentation.

**Action: NICE to forward members specific queries University of Liverpool have around staff costs.**

**Action: University of Liverpool to update the economic model in response to the Committee discussion.**

**7. Evidence reviews**

The Chair introduced Ella Novakovic, Senior Technical Analyst at NICE, who gave an overview of the findings for review 2, group 10 on drugs misuse prevention and the draft guideline recommendations. Ella thanked the Committee for all the comments received since the last meeting.

The Committee were given the opportunity to ask questions..

The Chair thanked Ella for her presentation.

**8. Drafting guideline recommendation and research recommendations**

The Committee discussed the draft guideline recommendations based on the evidence presented.

**Action: NICE to send updated draft recommendations to Committee via email. Committee to reply with comments on draft recommendations and draft research recommendations.**

**Action: NICE to circulate an updated version of the guideline, taking account of the committee discussion and additional comments received, in advance of the next meeting.**

**9. Summary of the day and next steps, including suggestions for expert testimony**

The Chair summarised the discussion from the day and highlighted that the next

## **PHAC C minutes 3<sup>rd</sup> March 2016**

meeting on this topic will be a 2 day meeting on the 25<sup>th</sup> and 26<sup>th</sup> April.

Papers to be mailed to members by close of play on 18<sup>th</sup> April.

### **10. Any other business**

There was no other business.

**Date of next meeting: 25<sup>th</sup> and 26<sup>th</sup> April**

**Location of next meeting:** Avonmouth House, London